Dextroamphetamine

From Wikipedia, the free encyclopedia
(Redirected from Dexamphetamine)

Template:Short description Template:DMCA Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Dextroamphetamine
INN: Dexamfetamine
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found. Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Pronunciation/ˌdɛkstroʊæmˈfɛtəmiːn/
Trade namesDexedrine, Zenzedi, others
Other namesd-Amphetamine, (S)-Amphetamine, S(+)-Amphetamine
AHFS/Drugs.comMonograph
MedlinePlusa605027
License dataPage Template:Plainlist/styles.css has no content.
Pregnancy
category		Page Template:Plainlist/styles.css has no content.
  • AU: B3
Dependence
liability		Physical: None
Psychological: Moderate[1]
Addiction
liability		Moderate[1]
Routes of
administration		By mouth, transdermal, intravenous, insufflation, rectal
Drug classStimulant
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
BioavailabilityOral: ~90%[9]
Protein binding15–40%[10]
MetabolismCYP2D6,[15] DBH,[21] FMO3[22]
Metabolites4-Hydroxyamphetamine[11]
Onset of actionIR dosing: 30–45 minutes[9][12]
XR dosing: 1.5–2 hours[13][14]
Elimination half-life9–11 hours[15][16]
pH-dependent: 7–34 hours[17]
Duration of actionIR dosing: 3–6 hours[13][18]
XR dosing: 8–12 hours[19][13][18]
ExcretionKidney (45%);[20][failed verification] urinary pH-dependent
Identifiers
  • (2S)-1-Phenylpropan-2-amine
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
E number{{#property:P628}}
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
ECHA InfoCard{{#property:P2566}}Template:EditAtWikidata
Chemical and physical data
FormulaC9H13N
Molar mass135.210 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
ChiralityDextrorotatory enantiomer
Density0.913 g/cm3
Boiling point201.5 °C (394.7 °F)
Solubility in water20mg per ml
  • C[C@@H](Cc1ccccc1)N
  • InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1 ☒N
  • Key:KWTSXDURSIMDCE-QMMMGPOBSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Dextroamphetamine is a central nervous system (CNS) stimulant and enantiomer of amphetamine that is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.[6][23] It is also used illicitly to enhance cognitive and athletic performance, and recreationally as an aphrodisiac and euphoriant. Dextroamphetamine is generally regarded as the prototypical stimulant.

The amphetamine molecule exists as two enantiomers, levoamphetamine and dextroamphetamine. Dextroamphetamine is the dextrorotatory, or 'right-handed', enantiomer and exhibits more pronounced effects on the central nervous system than levoamphetamine. Pharmaceutical dextroamphetamine sulfate is available as both a brand name and generic drug in a variety of dosage forms. Dextroamphetamine is sometimes prescribed as the inactive prodrug lisdexamfetamine.

Side effects of dextroamphetamine at therapeutic doses include elevated mood, decreased appetite, dry mouth, bruxism, headache, increased heart rate, increased wakefulness or insomnia, anxiety, and irritability, among others.[24] At excessive doses, psychosis (i.e., hallucinations, delusions), addiction, and rapid muscle breakdown may occur. However, for individuals with pre-existing psychotic disorders, there may be a risk of psychosis even at therapeutic doses.[25]

Dextroamphetamine, like other amphetamines, elicits its stimulating effects via several distinct actions: it inhibits or reverses the transporter proteins for the monoamine neurotransmitters (namely the serotonin, norepinephrine and dopamine transporters) either via trace amine-associated receptor 1 (TAAR1) or in a TAAR1 independent fashion when there are high cytosolic concentrations of the monoamine neurotransmitters[26] and it releases these neurotransmitters from synaptic vesicles via vesicular monoamine transporter 2 (VMAT2).[27] It also shares many chemical and pharmacological properties with human trace amines, particularly phenethylamine and N-methylphenethylamine, the latter being an isomer of amphetamine produced within the human body. It is available as a generic medication.[24] In 2023, mixed amphetamine salts (Adderall) was the 15th most commonly prescribed medication in the United States, with more than 32 million prescriptions.[28][29]

Page Template:TOC limit/styles.css has no content.

Uses

Medical

Dexedrine Spansule 5, 10, and 15 mg capsules, a sustained-release dosage form of dextroamphetamine

Dextroamphetamine is used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy,[6] and is sometimes prescribed off-label for depression and obesity.[23]

ADHD

{{#lsth:Amphetamine|ADHD}}

Narcolepsy

{{#lsth:Amphetamine|Narcolepsy}}

Enhancing performance

Page Module:Hatnote/styles.css has no content.

This section is transcluded from Script error: No such module "urldecode".. ([{{fullurl:Template:Absolute page title|action=edit}} edit] | [{{fullurl:Template:Absolute page title|action=history}} history])

{{#section-h:Amphetamine|Enhancing performance}}

Recreational

Dextroamphetamine is also used recreationally as a euphoriant and aphrodisiac, and, like other amphetamines, is used as a club drug for its energetic and euphoric high. Dextroamphetamine is considered to have a high potential for misuse in a recreational manner since individuals typically report feeling euphoric, more alert, and more energetic after taking the drug.[30][31][32] Dextroamphetamine's dopaminergic (rewarding) properties affect the mesocorticolimbic circuit; a group of neural structures responsible for incentive salience (i.e., "wanting"; desire or craving for a reward and motivation), positive reinforcement and positively-valenced emotions, particularly ones involving pleasure.[33] Large recreational doses of dextroamphetamine may produce dextroamphetamine overdose.[32] Recreational users sometimes open dexedrine capsules and crush the contents in order to insufflate (snort) it or subsequently dissolve it in water and inject it.[32] Immediate-release formulations have higher potential for abuse via insufflation (snorting) or intravenous injection due to a more favorable pharmacokinetic profile and easy crushability (especially tablets).[34][35]

The reason for using crushed spansules for insufflation and injection methods is evidently due to the instant-release forms of the drug seen in tablet preparations often containing a sizable amount of inactive binders and fillers alongside the active d-amphetamine, such as dextrose.[36] Injection into the bloodstream can be dangerous because insoluble fillers within the tablets can block small blood vessels.[32] Chronic overuse of dextroamphetamine can lead to severe drug dependence, resulting in withdrawal symptoms when drug use stops.[32]

Contraindications

Page Module:Hatnote/styles.css has no content.

This section is transcluded from Script error: No such module "urldecode".. ([{{fullurl:Template:Absolute page title|action=edit}} edit] | [{{fullurl:Template:Absolute page title|action=history}} history])

{{#section-h:Amphetamine|Contraindications}}

Adverse effects

Page Module:Hatnote/styles.css has no content.

This section is transcluded from Script error: No such module "urldecode".. ([{{fullurl:Template:Absolute page title|action=edit}} edit] | [{{fullurl:Template:Absolute page title|action=history}} history])

{{#section-h:Amphetamine|Adverse effects}}

Overdose

Page Module:Hatnote/styles.css has no content.

This section is transcluded from Script error: No such module "urldecode".. ([{{fullurl:Template:Absolute page title|action=edit}} edit] | [{{fullurl:Template:Absolute page title|action=history}} history])

{{#section-h:Amphetamine|Overdose}}

Interactions

Many types of substances are known to interact with amphetamine, resulting in altered drug action or metabolism of amphetamine, the interacting substance, or both.[15][37][25] Inhibitors of the enzymes that metabolize amphetamine (e.g., CYP2D6 and FMO3) will prolong its elimination half-life, meaning that its effects will last longer.[22][37][25] Amphetamine also interacts with MAOIs, particularly monoamine oxidase A inhibitors, since both MAOIs and amphetamine increase plasma catecholamines (i.e., norepinephrine and dopamine);[37][25] therefore, concurrent use of both is dangerous.[37][25] Amphetamine modulates the activity of most psychoactive drugs. In particular, amphetamine may decrease the effects of sedatives and depressants and increase the effects of stimulants and antidepressants.[37][25] Amphetamine may also decrease the effects of antihypertensives and antipsychotics due to its effects on blood pressure and dopamine respectively.[37][25] Zinc supplementation may reduce the minimum effective dose of amphetamine when it is used for the treatment of ADHD.[note 1][41] Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans.[42][43][44]

Pharmacology

Pharmacodynamics

Page Module:Hatnote/styles.css has no content.

Main section: Amphetamine § Pharmacodynamics
Monoamine release of amphetamine and related agents (EC50Tooltip Half maximal effective concentration, nM)
Compound NETooltip Norepinephrine DATooltip Dopamine 5-HTTooltip Serotonin Ref
Phenethylamine 10.9 39.5 >10,000 [45][46][47]
Dextroamphetamine 6.6–7.2 5.8–24.8 698–1,765 [48][49]
Levoamphetamine 9.5 27.7 ND [46][47]
Dextromethamphetamine 12.3–13.8 8.5–24.5 736–1,292 [48][50]
Levomethamphetamine 28.5 416 4,640 [48]
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs:[51][52]
Pharmacodynamics of amphetamine in a dopamine neuron
Lua error in package.lua at line 80: module 'Module:Navbar/configuration' not found.
A pharmacodynamic model of amphetamine and TAAR1
via AADC
The image above contains clickable links
Amphetamine enters the presynaptic neuron across the neuronal membrane or through DAT.[26] Once inside, it binds to TAAR1 or enters synaptic vesicles through VMAT2.[26][27][53] When amphetamine enters synaptic vesicles through VMAT2, it collapses the vesicular pH gradient, which in turn causes dopamine to be released into the cytosol (light tan-colored area) through VMAT2.[27][54] When amphetamine binds to TAAR1, it reduces the firing rate of the dopamine neuron via G protein-coupled inwardly rectifying potassium channels (GIRKs) and activates protein kinase A (PKA) and protein kinase C (PKC), which subsequently phosphorylate DAT.[26][55][56] PKA phosphorylation causes DAT to withdraw into the presynaptic neuron (internalize) and cease transport.[26] PKC-phosphorylated DAT may either operate in reverse or, like PKA-phosphorylated DAT, internalize and cease transport.[26][53] Amphetamine is also known to increase intracellular calcium, an effect which is associated with DAT phosphorylation through a CAMKIIα-dependent pathway, in turn producing dopamine efflux.[57][58]

Amphetamine and its enantiomers have been identified as potent full agonists of trace amine-associated receptor 1 (TAAR1), a GPCR, discovered in 2001, that is important for regulation of monoaminergic systems in the brain.[59][60] Activation of TAAR1 increases cAMP production via adenylyl cyclase activation and inhibits the function of the dopamine transporter, norepinephrine transporter, and serotonin transporter, as well as inducing the release of these monoamine neurotransmitters (effluxion).[26][59][61] Amphetamine enantiomers are also substrates for a specific neuronal synaptic vesicle uptake transporter called VMAT2.[27] When amphetamine is taken up by VMAT2, the vesicle releases (effluxes) dopamine, norepinephrine, and serotonin, among other monoamines, into the cytosol in exchange.[27]

Dextroamphetamine (the dextrorotary enantiomer) and levoamphetamine (the levorotary enantiomer) have identical pharmacodynamics, but their binding affinities to their biomolecular targets vary.[60][62] Dextroamphetamine is a more potent agonist of TAAR1 than levoamphetamine.[60] Consequently, dextroamphetamine produces roughly three to four times more central nervous system (CNS) stimulation than levoamphetamine;[60][62] however, levoamphetamine has slightly greater cardiovascular and peripheral effects.[62]

{{#section-h:Amphetamine|Related endogenous compounds}}

Pharmacokinetics

Page Module:Hatnote/styles.css has no content.

This section is transcluded from Script error: No such module "urldecode".. ([{{fullurl:Template:Absolute page title|action=edit}} edit] | [{{fullurl:Template:Absolute page title|action=history}} history])

{{#section-h:Amphetamine|Pharmacokinetics}}

History, society, and culture

Script error: No such module "Labelled list hatnote".

Racemic amphetamine was first synthesized under the chemical name "phenylisopropylamine" in Berlin, 1887 by the Romanian chemist Lazăr Edeleanu. It was not widely marketed until 1932, when the pharmaceutical company Smith, Kline & French (now known as GlaxoSmithKline) introduced it in the form of the Benzedrine inhaler for use as a bronchodilator. Notably, the amphetamine contained in the Benzedrine inhaler was the liquid free-base,[note 2] not a chloride or sulfate salt.

In 1935, the medical community became aware of the stimulant properties of amphetamine, specifically the dextroamphetamine isomer, and in 1937 Smith, Kline, and French introduced tablets under the brand name Dexedrine.[63] In the United States, Dexedrine was approved to treat narcolepsy and attention deficit hyperactivity disorder (ADHD).[6] In Canada indications once included epilepsy and parkinsonism.[64] Dextroamphetamine was marketed in various other forms in the following decades, primarily by Smith, Kline, and French, such as several combination medications including a mixture of dextroamphetamine and amobarbital (a barbiturate) sold under the brand name Dexamyl and, in the 1950s, an extended release capsule (the "Spansule").[65] Preparations containing dextroamphetamine were also used in World War II as a treatment against fatigue.[23]

It quickly became apparent that dextroamphetamine and other amphetamines had a high potential for misuse, although they were not heavily controlled until 1970, when the Comprehensive Drug Abuse Prevention and Control Act was passed by the United States Congress. Dextroamphetamine, along with other sympathomimetics, was eventually classified as Schedule II, the most restrictive category possible for a drug with a government-sanctioned, recognized medical use.[66] Internationally, it has been available under the names AmfeDyn (Italy), Curban (US), Obetrol (Switzerland), Simpamina (Italy), Dexedrine/GSK (US & Canada), Dexedrine/UCB (United Kingdom), Dextropa (Portugal), and Stild (Spain).[67] It became popular on the mod scene in England in the early 1960s, and carried through to the Northern Soul scene in the north of England to the end of the 1970s.

In October 2010, GlaxoSmithKline sold the rights for Dexedrine Spansule to Amedra Pharmaceuticals (a subsidiary of CorePharma).[68]

The U.S. Air Force uses dextroamphetamine as one of its "go pills", given to pilots on long missions to help them remain focused and alert. Conversely, "no-go pills" are used after the mission is completed, to combat the effects of the mission and "go-pills".[69][70][71] The Tarnak Farm incident was linked by media reports to the use of this drug on long term fatigued pilots. The military did not accept this explanation, citing the lack of similar incidents. Newer stimulant medications or awakeness promoting agents with different side effect profiles, such as modafinil, are being investigated and sometimes issued for this reason.[70]

Formulations

Dextroamphetamine pharmaceuticals and prodrugs[note 3]
Brand
name 		United States
Adopted Name 		(D:L) ratio Dosage
form 		Marketing
start date 		Sources
Adderall Mixed amphetamine salts 3:1 (salts) tablet 1996 [23][77]
Adderall XR Mixed amphetamine salts 3:1 (salts) capsule 2001 [23][77]
Mydayis Mixed amphetamine salts 3:1 (salts) capsule 2017 [78]
Adzenys XR-ODT amphetamine 3:1 (base) ODT 2016 [79][80]
Dyanavel XR amphetamine 3.2:1 (base) suspension 2015 [81][82]
Evekeo amphetamine sulfate 1:1 (salts) tablet 2012 [83] [84]
Dexedrine dextroamphetamine sulfate 1:0 (salts) capsule 1976 [23][77]
Zenzedi dextroamphetamine sulfate 1:0 (salts) tablet 2013 [77]
Vyvanse lisdexamfetamine dimesylate 1:0 (prodrug) capsule 2007 [23][85]
tablet
Xelstrym dextroamphetamine 1:0 (base) patch 2022 [7]

Transdermal dextroamphetamine patches

Dextroamphetamine is available as a transdermal patch containing dextroamphetamine base under the brand name Xelstrym.[7]

Dextroamphetamine sulfate

In the United States, immediate release (IR) formulations of dextroamphetamine sulfate are available generically as 5 mg and 10 mg tablets, marketed by Barr (Teva Pharmaceutical Industries), Mallinckrodt Pharmaceuticals, Wilshire Pharmaceuticals, Aurobindo Pharmaceutical USA and CorePharma. Previous IR tablets sold under the brand names Dexedrine and Dextrostat have been discontinued but in 2015, IR tablets became available by the brand name Zenzedi, offered as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 30 mg tablets.[86] Dextroamphetamine sulfate is also available as a controlled-release (CR) capsule preparation in strengths of 5 mg, 10 mg, and 15 mg under the brand name Dexedrine Spansule, with generic versions marketed by Barr and Mallinckrodt. A bubblegum flavored oral solution is available under the brand name ProCentra, manufactured by FSC Pediatrics, which is designed to be an easier method of administration in children who have difficulty swallowing tablets, each 5 mL contains 5 mg dextroamphetamine.[87] The conversion rate between dextroamphetamine sulfate to amphetamine free base is .728.[88]

In Australia, dexamfetamine is available in bottles of 100 instant release 5 mg tablets as a generic drug[89] or slow release dextroamphetamine preparations may be compounded by individual chemists.[90] In the United Kingdom, it is available in 5 mg instant release sulfate tablets under the generic name dexamfetamine sulfate as well as 10 mg and 20 mg strength tablets under the brand name Amfexa. It is also available in generic dexamfetamine sulfate 5 mg/ml oral sugar-free syrup.[91] The brand name Dexedrine was available in the United Kingdom prior to UCB Pharma disinvesting the product to another pharmaceutical company, Auden Mckenzie.[92]

Lisdexamfetamine

Script error: No such module "Labelled list hatnote".

Dextroamphetamine is the active metabolite of the prodrug lisdexamfetamine (L-lysine-dextroamphetamine), available by the brand name Vyvanse (Elvanse in the European market and Venvanse in the Brazilian market). Dextroamphetamine is liberated from lisdexamfetamine enzymatically following contact with red blood cells. The conversion is rate-limited by the enzyme, which prevents high blood concentrations of dextroamphetamine and reduces lisdexamfetamine's drug liking and abuse potential at clinical doses.[93][94] Vyvanse is marketed as once-a-day dosing as it provides a slow release of dextroamphetamine into the body. Vyvanse is available as capsules, and chewable tablets, and in seven strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The conversion rate between lisdexamfetamine dimesylate (Vyvanse) to dextroamphetamine base is 29.5%.[95][96][97]

Adderall

Script error: No such module "Labelled list hatnote".

Adderall tablets
Adderall 20 mg tablets, some broken in half, with a lengthwise-folded US dollar bill along the bottom

Another pharmaceutical that contains dextroamphetamine is commonly known by the brand name Adderall.[37][25] It is available as immediate release (IR) tablets and extended release (XR) capsules.[37][25] Adderall contains equal amounts of four amphetamine salts:[37][25]

Adderall has a total amphetamine base equivalence of 63%.[37][25] While the enantiomer ratio by dextroamphetamine salts to levoamphetamine salts is 3:1, the amphetamine base content is 75.9% dextroamphetamine, 24.1% levoamphetamine. [note 4]

Amphetamine base in marketed amphetamine medications
drug formula molar mass
[note 5] 		amphetamine base
[note 6] 		amphetamine base
in equal doses 		doses with
equal base
content
[note 7]
Page Template:Nobold/styles.css has no content.(g/mol) Page Template:Nobold/styles.css has no content.(percent) Page Template:Nobold/styles.css has no content.(30 mg dose)
total base total dextro- levo- dextro- levo-
dextroamphetamine sulfate[99][100] (C9H13N)2•H2SO4
368.49
270.41
73.38%
73.38%
—
22.0 mg
—
30.0 mg
amphetamine sulfate[101] (C9H13N)2•H2SO4
368.49
270.41
73.38%
36.69%
36.69%
11.0 mg
11.0 mg
30.0 mg
Adderall
62.57%
47.49%
15.08%
14.2 mg
4.5 mg
35.2 mg
25% dextroamphetamine sulfate[99][100] (C9H13N)2•H2SO4
368.49
270.41
73.38%
73.38%
—
25% amphetamine sulfate[101] (C9H13N)2•H2SO4
368.49
270.41
73.38%
36.69%
36.69%
25% dextroamphetamine saccharate[102] (C9H13N)2•C6H10O8
480.55
270.41
56.27%
56.27%
—
25% amphetamine aspartate monohydrate[103] (C9H13N)•C4H7NO4•H2O
286.32
135.21
47.22%
23.61%
23.61%
lisdexamfetamine dimesylate[85] C15H25N3O•(CH4O3S)2
455.49
135.21
29.68%
29.68%
—
8.9 mg
—
74.2 mg
amphetamine base suspension[81] C9H13N
135.21
135.21
100%
76.19%
23.81%
22.9 mg
7.1 mg
22.0 mg

Research

Schizophrenia

Dextroamphetamine reduces the negative symptoms of schizophrenia, and has been shown to enhance the effects of auditory discrimination training in schizophrenic patients.[104][105][106]

Notes

Page Template:Reflist/styles.css has no content.

  1. ^ The human dopamine transporter contains a high affinity extracellular zinc binding site which, upon zinc binding, inhibits dopamine reuptake and amplifies amphetamine-induced dopamine efflux in vitro.[38][39][40] The human serotonin transporter and norepinephrine transporter do not contain zinc binding sites.[40]
  2. ^ Free-base form amphetamine is a volatile oil, hence the efficacy of the inhalers.
  3. ^ These represent the current brands in the United States, except Dexedrine instant release tablets. Dexedrine tablets, introduced in 1937, is discontinued but available as Zenzedi and generically;[23][72] Dexedrine listed here represents the extended release "Spansule" capsule which was approved in 1976.[73][74] Amphetamine sulfate tablets, now sold as Evekeo (brand), were originally sold as Benzedrine (brand) sulfate in 1935[75][23] and discontinued sometime after 1982.[23][76]
  4. ^ Calculated by dextroamphetamine base percent / total amphetamine base percent = 47.49/62.57 = 75.90% from table: Amphetamine base in marketed amphetamine medications. The remainder is levoamphetamine.
  5. ^ For uniformity, molar masses were calculated using the Lenntech Molecular Weight Calculator[98] and were within 0.01 g/mol of published pharmaceutical values.
  6. ^ Amphetamine base percentage = molecular massbase / molecular masstotal. Amphetamine base percentage for Adderall = sum of component percentages / 4.
  7. ^ dose = (1 / amphetamine base percentage) × scaling factor = (molecular masstotal / molecular massbase) × scaling factor. The values in this column were scaled to a 30 mg dose of dextroamphetamine sulfate. Due to pharmacological differences between these medications (e.g., differences in the release, absorption, conversion, concentration, differing effects of enantiomers, half-life, etc.), the listed values should not be considered equipotent doses.
Image legend

Page Template:Reflist/styles.css has no content.

Reference notes

Page Template:Reflist/styles.css has no content.

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b Cite error: The named reference Stahl's Essential Psychopharmacology was invoked but never defined (see the help page).
  2. ^ Page Module:Citation/CS1/styles.css has no content."Therapeutic Goods (Poisons Standard—February 2023) Instrument 2022". Australian Government Federal Register of Legislation. 26 September 2022. Retrieved 9 January 2023.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Fuller K (20 February 2022). "ADHD Stimulant Prescribing Regulations & Authorities in Australia & New Zealand". AADPA. Retrieved 9 January 2023.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in português do Brasil). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  5. ^ Page Module:Citation/CS1/styles.css has no content."Product monograph brand safety updates". Health Canada. 6 June 2024. Retrieved 8 June 2024.
  6. ^ a b c d Page Module:Citation/CS1/styles.css has no content."Dexedrine spansule- dextroamphetamine sulfate capsule, extended release". DailyMed. 10 January 2022. Retrieved 28 March 2022.
  7. ^ a b c Page Module:Citation/CS1/styles.css has no content."Xelstrym- dextroamphetamine patch, extended release". DailyMed. 6 January 2023. Retrieved 21 January 2023.
  8. ^ Page Module:Citation/CS1/styles.css has no content."List of nationally authorised medicinal products : Active substance(s): dexamfetamine : Procedure No. PSUSA/00000986/202109" (PDF). Ema.europa.eu. Retrieved 5 June 2022.
  9. ^ a b Cite error: The named reference Antunes_2022 was invoked but never defined (see the help page).
  10. ^ Cite error: The named reference Drugbank-amph was invoked but never defined (see the help page).
  11. ^ https://go.drugbank.com/drugs/DB01576#:~:text=Dextroamphetamine-,4%2Dhydroxyamphetamine,-Route
  12. ^ Page Module:Citation/CS1/styles.css has no content.Green-Hernandez C, Singleton JK, Aronzon DZ (1 January 2001). Primary Care Pediatrics. Lippincott Williams & Wilkins. p. 243. ISBN 978-0-7817-2008-3.|quote = Table 21.2 Medications for ADHD ... D-amphetamine ... Onset: 30 min.
  13. ^ a b c Page Module:Citation/CS1/styles.css has no content.Millichap JG (2010). "Chapter 9: Medications for ADHD". In Millichap JG (ed.). Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD (2nd ed.). New York, USA: Springer. p. 112. ISBN 978-1-4419-1396-8.
    Table 9.2 Dextroamphetamine formulations of stimulant medication
    Dexedrine [Peak:2–3 h] [Duration:5–6 h] ...
    Adderall [Peak:2–3 h] [Duration:5–7 h]
    Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ...
    Adderall XR [Peak:7–8 h] [Duration:12 h]
    Vyvanse [Peak:3–4 h] [Duration:12 h]
  14. ^ Page Module:Citation/CS1/styles.css has no content.Brams M, Mao AR, Doyle RL (September 2008). "Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder". Postgrad. Med. 120 (3): 69–88. doi:10.3810/pgm.2008.09.1909. PMID 18824827. S2CID 31791162. Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours. ... MAS-XR, and LDX have a long duration of action at 12 hours postdose
  15. ^ a b c Cite error: The named reference FDA Pharmacokinetics was invoked but never defined (see the help page).
  16. ^ Page Module:Citation/CS1/styles.css has no content."Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet". DailyMed. 27 February 2022. Retrieved 21 January 2023.
  17. ^ Cite error: The named reference HSDB Toxnet October 2017 Full archived record was invoked but never defined (see the help page).
  18. ^ a b Page Module:Citation/CS1/styles.css has no content.Mignot EJ (October 2012). "A practical guide to the therapy of narcolepsy and hypersomnia syndromes". Neurotherapeutics. 9 (4): 739–752. doi:10.1007/s13311-012-0150-9. PMC 3480574. PMID 23065655.
  19. ^ Page Module:Citation/CS1/styles.css has no content.Stahl SM (March 2017). "Amphetamine (D)". Prescriber's Guide: Stahl's Essential Psychopharmacology (6th ed.). Cambridge, United Kingdom: Cambridge University Press. pp. 39–44. ISBN 978-1-108-22874-9. Retrieved 8 August 2017.
  20. ^ Page Module:Citation/CS1/styles.css has no content."dextrostat (dextroamphetamine sulfate) tablet [Shire US Inc.]". DailyMed. Wayne, PA: Shire US Inc. August 2006. Retrieved 8 November 2013.
  21. ^ Page Module:Citation/CS1/styles.css has no content.Lemke TL, Williams DA, Roche VF, Zito W (2013). Foye's Principles of Medicinal Chemistry (7th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 648. ISBN 978-1-60913-345-0. Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine.
  22. ^ a b Cite error: The named reference FMO was invoked but never defined (see the help page).
  23. ^ a b c d e f g h i j Page Module:Citation/CS1/styles.css has no content.Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). "Amphetamine, past and present—a pharmacological and clinical perspective". Journal of Psychopharmacology. 27 (6): 479–96. doi:10.1177/0269881113482532. PMC 3666194. PMID 23539642.
  24. ^ a b Page Module:Citation/CS1/styles.css has no content."Dextroamphetamine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 3 February 2019. Retrieved 2 February 2019.
  25. ^ a b c d e f g h i j k Page Module:Citation/CS1/styles.css has no content."Adderall XR- dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate capsule, extended release". DailyMed. 3 March 2022. Archived from the original on 15 July 2022. Retrieved 28 March 2022.
  26. ^ a b c d e f g Page Module:Citation/CS1/styles.css has no content.Miller GM (January 2011). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry. 116 (2): 164–176. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.
  27. ^ a b c d e Page Module:Citation/CS1/styles.css has no content.Eiden LE, Weihe E (January 2011). "VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse". Annals of the New York Academy of Sciences. 1216 (1): 86–98. Bibcode:2011NYASA1216...86E. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197. PMID 21272013.
  28. ^ Page Module:Citation/CS1/styles.css has no content."The Top 300 of 2023". ClinCalc. Archived from the original on 17 August 2025. Retrieved 17 August 2025.
  29. ^ Page Module:Citation/CS1/styles.css has no content."Dextroamphetamine; Dextroamphetamine Saccharate; Amphetamine; Amphetamine Aspartate Drug Usage Statistics, United States, 2014 - 2023". ClinCalc. Retrieved 17 August 2025.
  30. ^ Page Module:Citation/CS1/styles.css has no content."Commonly Abused Prescription Drugs Chart". National Institute on Drug Abuse. Retrieved 7 May 2012.
  31. ^ Page Module:Citation/CS1/styles.css has no content."Stimulant ADHD Medications – Methylphenidate and Amphetamines". National Institute on Drug Abuse. Archived from the original on 2 May 2012. Retrieved 7 May 2012.
  32. ^ a b c d e Page Module:Citation/CS1/styles.css has no content."National Institute on Drug Abuse. 2009. Stimulant ADHD Medications – Methylphenidate and Amphetamines". National Institute on Drug Abuse. Archived from the original on 27 January 2022. Retrieved 27 February 2013.
  33. ^ Page Module:Citation/CS1/styles.css has no content.Schultz W (2015). "Neuronal reward and decision signals: from theories to data". Physiological Reviews. 95 (3): 853–951. doi:10.1152/physrev.00023.2014. PMC 4491543. PMID 26109341. Rewards in operant conditioning are positive reinforcers. ... Operant behavior gives a good definition for rewards. Anything that makes an individual come back for more is a positive reinforcer and therefore a reward. Although it provides a good definition, positive reinforcement is only one of several reward functions. ... Rewards are attractive. They are motivating and make us exert an effort. ... Rewards induce approach behavior, also called appetitive or preparatory behavior, sexual behavior, and consummatory behavior. ... Thus any stimulus, object, event, activity, or situation that has the potential to make us approach and consume it is by definition a reward. ... Rewarding stimuli, objects, events, situations, and activities consist of several major components. First, rewards have basic sensory components (visual, auditory, somatosensory, gustatory, and olfactory) ... Second, rewards are salient and thus elicit attention, which are manifested as orienting responses. The salience of rewards derives from three principal factors, namely, their physical intensity and impact (physical salience), their novelty and surprise (novelty/surprise salience), and their general motivational impact shared with punishers (motivational salience). A separate form not included in this scheme, incentive salience, primarily addresses dopamine function in addiction and refers only to approach behavior (as opposed to learning) ... Third, rewards have a value component that determines the positively motivating effects of rewards and is not contained in, nor explained by, the sensory and attentional components. This component reflects behavioral preferences and thus is subjective and only partially determined by physical parameters. Only this component constitutes what we understand as a reward. It mediates the specific behavioral reinforcing, approach generating, and emotional effects of rewards that are crucial for the organism's survival and reproduction, whereas all other components are only supportive of these functions. ... Rewards can also be intrinsic to behavior. They contrast with extrinsic rewards that provide motivation for behavior and constitute the essence of operant behavior in laboratory tests. Intrinsic rewards are activities that are pleasurable on their own and are undertaken for their own sake, without being the means for getting extrinsic rewards. ... Intrinsic rewards are genuine rewards in their own right, as they induce learning, approach, and pleasure, like perfectioning, playing, and enjoying the piano. Although they can serve to condition higher order rewards, they are not conditioned, higher order rewards, as attaining their reward properties does not require pairing with an unconditioned reward. ... These emotions are also called liking (for pleasure) and wanting (for desire) in addiction research and strongly support the learning and approach generating functions of reward.
  34. ^ Page Module:Citation/CS1/styles.css has no content.Canadian ADHD Practice Guidelines (PDF) (Fourth ed.). Canadian ADHD Resource Alliance. 2018. p. 67. Archived from the original (PDF) on 2 May 2023. Retrieved 2 May 2023.
  35. ^ Page Module:Citation/CS1/styles.css has no content.Bright GM (May 2008). "Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey". Medscape Journal of Medicine. 10 (5): 111. PMC 2438483. PMID 18596945.
  36. ^ Page Module:Citation/CS1/styles.css has no content.Childs E, de Wit H (November 2013). "Contextual conditioning enhances the psychostimulant and incentive properties of d-amphetamine in humans". Addiction Biology. 18 (6): 985–992. doi:10.1111/j.1369-1600.2011.00416.x. PMC 4242554. PMID 22129527.
  37. ^ a b c d e f g h i j Page Module:Citation/CS1/styles.css has no content."Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet". DailyMed. 27 February 2022. Retrieved 28 March 2022.
  38. ^ Page Module:Citation/CS1/styles.css has no content.Krause J (April 2008). "SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder". Expert Rev. Neurother. 8 (4): 611–625. doi:10.1586/14737175.8.4.611. PMID 18416663. S2CID 24589993. Zinc binds at ... extracellular sites of the DAT [103], serving as a DAT inhibitor. In this context, controlled double-blind studies in children are of interest, which showed positive effects of zinc [supplementation] on symptoms of ADHD [105,106]. It should be stated that at this time [supplementation] with zinc is not integrated in any ADHD treatment algorithm.
  39. ^ Page Module:Citation/CS1/styles.css has no content.Sulzer D (February 2011). "How addictive drugs disrupt presynaptic dopamine neurotransmission". Neuron. 69 (4): 628–649. doi:10.1016/j.neuron.2011.02.010. PMC 3065181. PMID 21338876. They did not confirm the predicted straightforward relationship between uptake and release, but rather that some compounds including AMPH were better releasers than substrates for uptake. Zinc, moreover, stimulates efflux of intracellular [3H]DA despite its concomitant inhibition of uptake (Scholze et al., 2002).
  40. ^ a b Page Module:Citation/CS1/styles.css has no content.Scholze P, Nørregaard L, Singer EA, Freissmuth M, Gether U, Sitte HH (June 2002). "The role of zinc ions in reverse transport mediated by monoamine transporters". J. Biol. Chem. 277 (24): 21505–21513. doi:10.1074/jbc.M112265200. PMID 11940571.
  41. ^ Page Module:Citation/CS1/styles.css has no content.Scassellati C, Bonvicini C, Faraone SV, Gennarelli M (October 2012). "Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses". J. Am. Acad. Child Adolesc. Psychiatry. 51 (10): 1003–1019.e20. doi:10.1016/j.jaac.2012.08.015. PMID 23021477.
  42. ^ Page Module:Citation/CS1/styles.css has no content.Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, et al. (April 2013). "A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability". J Child Adolesc Psychopharmacol. 23 (3): 179–193. doi:10.1089/cap.2012.0093. PMC 3696926. PMID 23560600.
  43. ^ Page Module:Citation/CS1/styles.css has no content.Heal DJ, Smith SL, Findling RL (2012). "ADHD: current and future therapeutics". Behavioral Neuroscience of Attention Deficit Hyperactivity Disorder and Its Treatment. Current Topics in Behavioral Neurosciences. Vol. 9. pp. 361–390. doi:10.1007/7854_2011_125. ISBN 978-3-642-24611-1. PMID 21487953. Adjunctive therapy with DL-methylphenidate in atomoxetine partial responders has been successful (Wilens et al. 2009), but this also increases the rates of insomnia, irritability and loss of appetite (Hammerness et al. 2009). This combination therapy has not included amphetamine because blockade of NET by atomoxetine prevents entry of amphetamine into presynaptic noradrenergic terminals (Sofuoglu et al. 2009).
  44. ^ Page Module:Citation/CS1/styles.css has no content.Sofuoglu M, Poling J, Hill K, Kosten T (2009). "Atomoxetine attenuates dextroamphetamine effects in humans". Am J Drug Alcohol Abuse. 35 (6): 412–416. doi:10.3109/00952990903383961. PMC 2796580. PMID 20014909.
  45. ^ Page Module:Citation/CS1/styles.css has no content.Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. (February 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026.
  46. ^ a b Page Module:Citation/CS1/styles.css has no content.Forsyth AN (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines". ScholarWorks@UNO. Retrieved 4 November 2024.
  47. ^ a b Page Module:Citation/CS1/styles.css has no content.Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W.
  48. ^ a b c Page Module:Citation/CS1/styles.css has no content.Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707.
  49. ^ Page Module:Citation/CS1/styles.css has no content.Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836.
  50. ^ Page Module:Citation/CS1/styles.css has no content.Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology. 37 (5): 1192–1203. doi:10.1038/npp.2011.304. PMC 3306880. PMID 22169943.
  51. ^ Page Module:Citation/CS1/styles.css has no content.Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs". Eur J Pharmacol. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135.
  52. ^ Page Module:Citation/CS1/styles.css has no content.Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
  53. ^ a b Page Module:Citation/CS1/styles.css has no content.Quintero J, Gutiérrez-Casares JR, Álamo C (11 August 2022). "Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review". Neurology and Therapy. 11 (4): 1489–1517. doi:10.1007/s40120-022-00392-2. PMC 9588136. PMID 35951288. The active form of the drug has a central nervous system stimulating activity by the primary inhibition of DAT, NET, trace amine-associated receptor 1 (TAAR1) and vesicular monoamine transporter 2 (SLC18A2), among other targets, therefore regulating the reuptake and release of catecholamines (primarily NE and DA) on the synaptic cleft. ...
    LDX can also promote the increase of DA in the synaptic cleft by activating protein TAAR1, which produces the efflux of monoamine NTs, mainly DA, from storage sites on presynaptic neurons. TAAR1 activation leads to intracellular cAMP signalling that results in PKA and PKC phosphorylation and activation. This PKC activation decreases DAT1, NET1 and SERT cell surface expression, intensifying the direct blockage of monoamine transporters by LDX and improving the neurotransmission imbalance in ADHD.
  54. ^ Page Module:Citation/CS1/styles.css has no content.Sulzer D, Cragg SJ, Rice ME (August 2016). "Striatal dopamine neurotransmission: regulation of release and uptake". Basal Ganglia. 6 (3): 123–148. doi:10.1016/j.baga.2016.02.001. PMC 4850498. PMID 27141430. Despite the challenges in determining synaptic vesicle pH, the proton gradient across the vesicle membrane is of fundamental importance for its function. Exposure of isolated catecholamine vesicles to protonophores collapses the pH gradient and rapidly redistributes transmitter from inside to outside the vesicle. ... Amphetamine and its derivatives like methamphetamine are weak base compounds that are the only widely used class of drugs known to elicit transmitter release by a non-exocytic mechanism. As substrates for both DAT and VMAT, amphetamines can be taken up to the cytosol and then sequestered in vesicles, where they act to collapse the vesicular pH gradient.
  55. ^ Page Module:Citation/CS1/styles.css has no content.Ledonne A, Berretta N, Davoli A, Rizzo GR, Bernardi G, Mercuri NB (July 2011). "Electrophysiological effects of trace amines on mesencephalic dopaminergic neurons". Front. Syst. Neurosci. 5: 56. doi:10.3389/fnsys.2011.00056. PMC 3131148. PMID 21772817. Three important new aspects of TAs action have recently emerged: (a) inhibition of firing due to increased release of dopamine; (b) reduction of D2 and GABAB receptor-mediated inhibitory responses (excitatory effects due to disinhibition); and (c) a direct TA1 receptor-mediated activation of GIRK channels which produce cell membrane hyperpolarization.
  56. ^ Page Module:Citation/CS1/styles.css has no content."TAAR1". GenAtlas. University of Paris. 28 January 2012. Retrieved 29 May 2014.  • tonically activates inwardly rectifying K(+) channels, which reduces the basal firing frequency of dopamine (DA) neurons of the ventral tegmental area (VTA)
  57. ^ Page Module:Citation/CS1/styles.css has no content.Underhill SM, Wheeler DS, Li M, Watts SD, Ingram SL, Amara SG (July 2014). "Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons". Neuron. 83 (2): 404–416. doi:10.1016/j.neuron.2014.05.043. PMC 4159050. PMID 25033183. AMPH also increases intracellular calcium (Gnegy et al., 2004) that is associated with calmodulin/CamKII activation (Wei et al., 2007) and modulation and trafficking of the DAT (Fog et al., 2006; Sakrikar et al., 2012). ... For example, AMPH increases extracellular glutamate in various brain regions including the striatum, VTA and NAc (Del Arco et al., 1999; Kim et al., 1981; Mora and Porras, 1993; Xue et al., 1996), but it has not been established whether this change can be explained by increased synaptic release or by reduced clearance of glutamate. ... DHK-sensitive, EAAT2 uptake was not altered by AMPH (Figure 1A). The remaining glutamate transport in these midbrain cultures is likely mediated by EAAT3 and this component was significantly decreased by AMPH
  58. ^ Page Module:Citation/CS1/styles.css has no content.Vaughan RA, Foster JD (September 2013). "Mechanisms of dopamine transporter regulation in normal and disease states". Trends Pharmacol. Sci. 34 (9): 489–496. doi:10.1016/j.tips.2013.07.005. PMC 3831354. PMID 23968642. AMPH and METH also stimulate DA efflux, which is thought to be a crucial element in their addictive properties [80], although the mechanisms do not appear to be identical for each drug [81]. These processes are PKCβ– and CaMK–dependent [72, 82], and PKCβ knock-out mice display decreased AMPH-induced efflux that correlates with reduced AMPH-induced locomotion [72].
  59. ^ a b Page Module:Citation/CS1/styles.css has no content.Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. (December 2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor". Molecular Pharmacology. 60 (6): 1181–1188. doi:10.1124/mol.60.6.1181. PMID 11723224. S2CID 14140873.
  60. ^ a b c d Page Module:Citation/CS1/styles.css has no content.Lewin AH, Miller GM, Gilmour B (December 2011). "Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class". Bioorg. Med. Chem. 19 (23): 7044–7048. doi:10.1016/j.bmc.2011.10.007. PMC 3236098. PMID 22037049.
  61. ^ Page Module:Citation/CS1/styles.css has no content.Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, et al. (July 2001). "Trace amines: identification of a family of mammalian G protein-coupled receptors". Proceedings of the National Academy of Sciences of the United States of America. 98 (16): 8966–8971. Bibcode:2001PNAS...98.8966B. doi:10.1073/pnas.151105198. PMC 55357. PMID 11459929.
  62. ^ a b c Page Module:Citation/CS1/styles.css has no content.Westfall DP, Westfall TC (2010). "Miscellaneous Sympathomimetic Agonists". In Brunton LL, Chabner BA, Knollmann BC (eds.). Goodman & Gilman's Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill. ISBN 978-0-07-162442-8.
  63. ^ Page Module:Citation/CS1/styles.css has no content."Dexedrine". Medic8. Archived from the original on 19 December 2009. Retrieved 27 November 2013.
  64. ^ Page Module:Citation/CS1/styles.css has no content."Dextroamphetamine [monograph]". Internet Mental Health. Archived from the original on 27 April 2006. Retrieved 6 September 2015.
  65. ^ Page Module:Citation/CS1/styles.css has no content."Information on Dexedrine: A Quick Review | Weitz & Luxenberg". Weitzlux.com. 31 August 2013. Retrieved 5 January 2017.
  66. ^ Page Module:Citation/CS1/styles.css has no content.King DG (4 January 2017). "Prescription Forgery". Handwriting Services International. Archived from the original on 5 July 2008.
  67. ^ Page Module:Citation/CS1/styles.css has no content.Sittig M, ed. (January 1988). Pharmaceutical Manufacturing Encyclopedia. Vol. 1 (2nd ed.). Noyes Publications. ISBN 978-0-8155-1144-1.
  68. ^ Page Module:Citation/CS1/styles.css has no content."Dexedrine FAQs". Archived from the original on 17 June 2011.
  69. ^ Page Module:Citation/CS1/styles.css has no content.Bonné J (9 January 2003). "'Go pills': A war on drugs?". NBC News. Retrieved 5 January 2017.
  70. ^ a b Page Module:Citation/CS1/styles.css has no content.Woodring JC. "Air Force scientists battle aviator fatigue". Archived from the original on 14 October 2012. Retrieved 5 January 2017.
  71. ^ Page Module:Citation/CS1/styles.css has no content.Emonson DL, Vanderbeek RD (1995). "The use of amphetamines in U.S. Air Force tactical operations during Desert Shield and Storm". Aviation, Space, and Environmental Medicine. 66 (3): 260–3. PMID 7661838.
  72. ^ Page Module:Citation/CS1/styles.css has no content."Drugs@FDA: Dexedrine". U.S. Food and Drug Administration (FDA). Archived from the original on 31 July 2024. Retrieved 28 March 2022.
  73. ^ Page Module:Citation/CS1/styles.css has no content."Drugs@FDA: Dexedrine". U.S. Food and Drug Administration (FDA). Archived from the original on 16 February 2017. Retrieved 28 March 2022.
  74. ^ Page Module:Citation/CS1/styles.css has no content."Drugs@FDA: Dexedrine: Label and Approval History". U.S. Food and Drug Administration (FDA). Archived from the original on 28 August 2021. Retrieved 30 December 2015. 08/02/1976 ... Approval
  75. ^ Page Module:Citation/CS1/styles.css has no content.Strohl MP (March 2011). "Bradley's Benzedrine studies on children with behavioral disorders". The Yale Journal of Biology and Medicine. 84 (1): 27–33. PMC 3064242. PMID 21451781. Bradley experimented with Benzedrine sulfate, a drug marketed to doctors by the company Smith, Kline & French (SKF) between 1935 and 1937...
  76. ^ Page Module:Citation/CS1/styles.css has no content."FDA Approved Drug Products: Label and Approval History (Benzedrine)". U.S. Food and Drug Administration (FDA). Archived from the original on 2 July 2010. Retrieved 11 March 2016. Action Date 5/11/1982, Supplement Number 007, Approval Type Chemistry
  77. ^ a b c d Page Module:Citation/CS1/styles.css has no content."National Drug Code Amphetamine Search Results". National Drug Code Directory. U.S. Food and Drug Administration (FDA). Archived from the original on 16 December 2013. Retrieved 16 December 2013.
  78. ^ Page Module:Citation/CS1/styles.css has no content."Mydayis- dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate capsule, extended release". DailyMed. 28 October 2022. Retrieved 21 January 2023.
  79. ^ Page Module:Citation/CS1/styles.css has no content."Adzenys XR-ODT- amphetamine tablet, orally disintegrating". DailyMed. 10 March 2022. Retrieved 21 January 2023.
  80. ^ Page Module:Citation/CS1/styles.css has no content."Drug Approval Package: Adzenys XR-ODT (amphetamine)". U.S. Food and Drug Administration (FDA). 27 January 2016. Archived from the original on 10 January 2017. Retrieved 21 January 2023.
  81. ^ a b Cite error: The named reference Dyanavel was invoked but never defined (see the help page).
  82. ^ Page Module:Citation/CS1/styles.css has no content."Drug Approval Package: Dyanavel XR". U.S. Food and Drug Administration (FDA). 21 March 2022. Archived from the original on 27 October 2022. Retrieved 21 January 2023.
  83. ^ Cite error: The named reference Evekeo was invoked but never defined (see the help page).
  84. ^ Page Module:Citation/CS1/styles.css has no content."Evekeo". U.S. Food and Drug Administration (FDA). Archived from the original on 17 February 2017. Retrieved 11 August 2015.
  85. ^ a b Page Module:Citation/CS1/styles.css has no content."Vyvanse Prescribing Information" (PDF). United States Food and Drug Administration. Shire US Inc. May 2017. pp. 17–21. Retrieved 10 July 2017.
  86. ^ Page Module:Citation/CS1/styles.css has no content."Zenzedi (dextroamphetamine sulfate, USP)". Zenzedi.com. Retrieved 5 January 2017.
  87. ^ Page Module:Citation/CS1/styles.css has no content."ProCentra (dextroamphetamine sulfate 5 mg/5 mL Oral Solution)". FSC Laboratories. Archived from the original on 5 October 2010.
  88. ^ Page Template:Citation/styles.css has no content.US 7655630, Mickle T, Krishnan S, Bishop B, Lauderback C, Moncrief JS, Oberlender R, Piccariello T, Paul BJ, Verbicky CD, "Abuse-resistant amphetamine prodrugs", issued Script error: No such module "auto date formatter"., assigned to Takeda Pharmaceutical Co Ltd 
  89. ^ Page Module:Citation/CS1/styles.css has no content.Hazell P (1995). "Stimulant treatment for attention deficit hyperactivity disorder". Australian Prescriber. 18 (3): 60–63. doi:10.18773/austprescr.1995.064.
  90. ^ Page Module:Citation/CS1/styles.css has no content."Pharmaceutical Services". .health.nsw.gov.au. Archived from the original on 5 May 2013. Retrieved 5 January 2017.
  91. ^ Page Module:Citation/CS1/styles.css has no content."Dexamfetamine sulphate - Medicinal forms". British National Formulary. BMJ Group and Pharmaceutical Press (Royal Pharmaceutical Society). Retrieved 9 November 2019.
  92. ^ Page Module:Citation/CS1/styles.css has no content."Dexamfetamine – Prescribe Generically" (PDF). Red/Amber News (22). Interface Pharmacist Network Specialist Medicines (IPNSM): 2. November 2010. Archived from the original (PDF) on 18 May 2013. Retrieved 20 April 2012.
  93. ^ Page Module:Citation/CS1/styles.css has no content.Hutson PH, Pennick M, Secker R (December 2014). "Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug". Neuropharmacology. 87: 41–50. doi:10.1016/j.neuropharm.2014.02.014. PMID 24594478. S2CID 37893582.
  94. ^ Page Module:Citation/CS1/styles.css has no content.Elayan I (2006). "NRP-104 (lisdexamphetamine dimesylate)" (PDF). Pharmacology/Toxicology Review and Evaluation. U.S. Food and Drug Administration. pp. 18–19. Archived from the original (PDF) on 11 February 2017.
  95. ^ Page Module:Citation/CS1/styles.css has no content.Mohammadi M, Akhondzadeh S (September 2011). "Advances and considerations in attention-deficit/hyperactivity disorder pharmacotherapy". Acta Medica Iranica. 49 (8): 487–498. PMID 22009816. Archived from the original on 12 March 2014. Retrieved 12 March 2014.
  96. ^ Page Module:Citation/CS1/styles.css has no content.Heal DJ, Buckley NW, Gosden J, Slater N, France CP, Hackett D (October 2013). "A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil". Neuropharmacology. 73: 348–358. doi:10.1016/j.neuropharm.2013.05.021. PMID 23748096. S2CID 25343254.
  97. ^ Page Module:Citation/CS1/styles.css has no content.Rowley HL, Kulkarni R, Gosden J, Brammer R, Hackett D, Heal DJ (November 2012). "Lisdexamfetamine and immediate release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity". Neuropharmacology. 63 (6): 1064–1074. doi:10.1016/j.neuropharm.2012.07.008. PMID 22796358. S2CID 29702399.
  98. ^ Page Module:Citation/CS1/styles.css has no content."Molecular Weight Calculator". Lenntech. Retrieved 19 August 2015.
  99. ^ a b Page Module:Citation/CS1/styles.css has no content."Dextroamphetamine Sulfate USP". Mallinckrodt Pharmaceuticals. March 2014. Retrieved 19 August 2015.
  100. ^ a b Page Module:Citation/CS1/styles.css has no content."D-amphetamine sulfate". Tocris. 2015. Retrieved 19 August 2015.
  101. ^ a b Page Module:Citation/CS1/styles.css has no content."Amphetamine Sulfate USP". Mallinckrodt Pharmaceuticals. March 2014. Retrieved 19 August 2015.
  102. ^ Page Module:Citation/CS1/styles.css has no content."Dextroamphetamine Saccharate". Mallinckrodt Pharmaceuticals. March 2014. Retrieved 19 August 2015.
  103. ^ Page Module:Citation/CS1/styles.css has no content."Amphetamine Aspartate". Mallinckrodt Pharmaceuticals. March 2014. Retrieved 19 August 2015.
  104. ^ Page Module:Citation/CS1/styles.css has no content.Lindenmayer JP, Nasrallah H, Pucci M, James S, Citrome L (July 2013). "A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities". Schizophrenia Research. 147 (2–3): 241–252. doi:10.1016/j.schres.2013.03.019. PMID 23619055.
  105. ^ Page Module:Citation/CS1/styles.css has no content.van Kammen DP, Boronow JJ (April 1988). "Dextro-amphetamine diminishes negative symptoms in schizophrenia". International Clinical Psychopharmacology. 3 (2): 111–121. doi:10.1097/00004850-198804000-00002. PMID 3294284.
  106. ^ Page Module:Citation/CS1/styles.css has no content.Swerdlow NR, Tarasenko M, Bhakta SG, Talledo J, Alvarez AI, Hughes EL, et al. (July 2017). "Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients". Schizophrenia Bulletin. 43 (4): 872–880. doi:10.1093/schbul/sbw148. PMC 5472129. PMID 27798224.{{cite journal}}: CS1 maint: overridden setting (link)

Page Module:Side box/styles.css has no content.Page Template:Sister project/styles.css has no content.

Page Template:Plainlist/styles.css has no content.
Script error: No such module "Sister project logo".
Wikimedia Commons has media related to [[commons:Template:If then show|Template:If then show]].

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:ADHD pharmacotherapies Template:Wakefulness-promoting agents Template:Monoamine releasing agents Template:Monoaminergic activity enhancers Template:TAAR ligands Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:GlaxoSmithKline Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "http://cosmopedia.co/index.php?title=Dextroamphetamine&oldid=291436"